口服降糖药是临床中常用的2型糖尿病血糖管理方案。除了二甲双胍等经典的降糖药外,近年来,二肽基肽酶-4(DPP-4)抑制剂、钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂等新型降糖药物的上市为糖尿病的治疗提供了更多的选择。目前,2型糖尿病口服降糖药物根据作用机制不同主要分为以下7类(见表1),可谓是糖尿病口服降糖药物治疗中的“七仙女”。
表1 常用口服降糖药物的分类和作用特点[1]
然而,有很多医患对常见几类口服降糖药物存在较多的认识误区,错误的认知有可能导致用药失误等问题,极大的影响了糖尿病的治疗达标率。小编总结了目前临床常见的几个口服降糖药的认识误区,并进行纠正,来看看你中招了吗?
参考资料(可上下滑动查看)
[1]中华医学会内分泌学分会. 中国成人2型糖尿病口服降糖药联合治疗专家共识[J]. 中华内分泌代谢杂志, 2019, 35(3):10.
[2]Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2010(4):CD002967.
[3]Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668-2675.
[4]Ji L, Li H, Guo X, Li Y, Hu R, Zhu Z. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One. 2013;8(2):e57222.
[5]母义明, 杨文英, 朱大龙,等. 磺脲类药物临床应用专家共识(2016年版)[J]. 药品评价, 2017.
[6]Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007 Jul 5;357(1):100.]. N Engl J Med. 2007;356(24):2457-2471.
[7]Bach RG, Brooks MM, Lombardero M, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2013;128(8):785-794.
[8]Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369. Published 2012 Mar 12.
联系客服